Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00455
|
|||||
| Drug Name |
Dicloxacillin
|
|||||
| Synonyms |
(2S,5R,6R)-6-({[3-(2,6-dichlorophenyl)-5-methyl-1,2-oxazol-4-yl]carbonyl}amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-({[3-(2,6-dichlorophenyl)-5-methylisoxazol-4-yl]carbonyl}amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-[[3-(2,6-dichlorophenyl)-5-methyl-1,2-oxazole-4-carbonyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 3-(2,6-Dichlorophenyl)-5-methyl-4-isoxazolylpenicillin; 6-(3-(2,6-Dichlorophenyl)-5-methyl-4-isoxazolecarboxamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid; 6-(3-(2,6-Dichlorophenyl)-5-methyl-4-isoxazolecarboxamido)penicillanic acid; 6beta-{[3-(2,6-dichlorophenyl)-5-methyl-1,2-oxazol-4-yl]carboxamido}-2,2-dimethylpenam-3alpha-carboxylic acid; BRL 1702; Dichloroxacillin; Diclocil (TN); Diclossacillina; Diclossacillina [DCIT]; Dicloxaciclin; Dicloxacilin; Dicloxacilina; Dicloxacilina [INN-Spanish]; Dicloxacillin (USAN/INN); Dicloxacillin [USAN:INN:BAN]; Dicloxacillin sodium; Dicloxacillin, Monosodium Salt, Mono-Hydrate; Dicloxacilline; Dicloxacilline [INN-French]; Dicloxacillinum; Dicloxacillinum [INN-Latin]; Dicloxacycline; Dycill; Dynapen; Maclicine; Methyldichlorophenylisoxazolylpenicillin; Pathocil; R-13423
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Susceptible gram-positive bacteria infections [ICD11:1A00-1H0Z] | Approved | [1] | |||
| Therapeutic Class |
Antibiotics
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C19H17Cl2N3O5S
|
|||||
| Canonical SMILES |
CC1=C(C(=NO1)C2=C(C=CC=C2Cl)Cl)C(=O)NC3C4N(C3=O)C(C(S4)(C)C)C(=O)O
|
|||||
| InChI |
InChI=1S/C19H17Cl2N3O5S/c1-7-10(12(23-29-7)11-8(20)5-4-6-9(11)21)15(25)22-13-16(26)24-14(18(27)28)19(2,3)30-17(13)24/h4-6,13-14,17H,1-3H3,(H,22,25)(H,27,28)/t13-,14+,17-/m1/s1
|
|||||
| InChIKey |
YFAGHNZHGGCZAX-JKIFEVAISA-N
|
|||||
| CAS Number |
CAS 3116-76-5
|
|||||
| Pharmaceutical Properties | Molecular Weight | 470.3 | Topological Polar Surface Area | 138 | ||
| Heavy Atom Count | 30 | Rotatable Bond Count | 4 | |||
| Hydrogen Bond Donor Count | 2 | Hydrogen Bond Acceptor Count | 7 | |||
| XLogP |
2.9
|
|||||
| PubChem CID | ||||||
| PubChem SID |
103234555
,104133803
,104344973
,11335833
,11361072
,11363826
,11366388
,11368950
,11371491
,11374192
,11377112
,11462044
,11466478
,11467598
,11484777
,11486175
,11488797
,11490202
,11492322
,11494746
,117541882
,124766323
,134222806
,134337731
,134981835
,135912430
,136357162
,137003736
,140093221
,142567322
,14960168
,29286044
,46508182
,47216776
,47440256
,47736481
,47810752
,47810753
,48259229
,48334496
,48415884
,50064670
,50783422
,57304808
,57330050
,7849407
,7979067
,8163742
,85788067
,9165
|
|||||
| ChEBI ID |
ChEBI:4511
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [2] | |
| PEPT1 | Transporter Info | Peptide transporter 1 | Substrate | [3] | ||
| PEPT2 | Transporter Info | Peptide transporter 2 | Substrate | [3] | ||
| References | ||||||
| 1 | Dicloxacillin was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Can the enhanced renal clearance of antibiotics in cystic fibrosis patients be explained by P-glycoprotein transport? Pharm Res. 2002 Apr;19(4):457-62. | |||||
| 3 | Transport characteristics of a novel peptide transporter 1 substrate, antihypotensive drug midodrine, and its amino acid derivatives. J Pharmacol Exp Ther. 2006 Jul;318(1):455-60. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.